Vianti Capital Fund I

Vianti Capital is a Boston-based venture capital firm founded in 2025 that specializes in therapeutics and drug discovery investments. Led by Founder and Managing Partner Arjun Goyal, a former co-founder of Vida Ventures, the firm focuses on biotechnology companies applying data-driven approaches such as machine learning and computational biology to develop novel therapies. Vianti Capital Fund I is the firm's primary investment vehicle, which targets innovative companies in the immunology, oncology, and rare disease sectors. The fund has participated in significant industry financings, including the $225 million PIPE for Talawar Therapeutics to advance bispecific antibody programs for inflammatory diseases.